Skip to content

Study · Not a test of the peptide alone · 1999

1 result

Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.

Csernus V, Schally AV, Groot K

Peptides1 Jan 1999Cited by 23 (Europe PMC)

PMID10477085 (opens in a new tab)DOI10.1016/s0196-9781(99)00071-6 (opens in a new tab)PepBankPUB-10477085
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01LabNot a test of Sermorelin aloneIn vitro (cells)Activity measurement

    In human mammary, prostatic and pancreatic cancer cells, the GHRH antagonist MZ-5-156 at 100 to 200 nM inhibited GHRH-induced cAMP release.

    In plain wordsIn lab-grown human cancer cells, the drug MZ-5-156 blocked the cAMP signal that GHRH normally triggers.

    Peptide
    Sermorelin
    Outcome
    DecreaseGHRH-induced cAMP release
    Study

    humann: not reported in source

    Cultured human mammary, prostatic and pancreatic cancer cells (MDA-MB-468, PC-3, SW-1990, CAPAN-2) in a superfusion system
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    GHRH antagonist MZ-5-156 at 100 to 200 nM concentration inhibited the GHRH- or VIP-induced cAMP release from mammary (MDA-MB-468), prostatic (PC-3), and pancreatic (SW-1990 and CAPAN-2) cancer cells.
    1 context sentence
    Summary · context
    Various human cancer cell lines were exposed to human GHRH(1-29)NH2 (2-20 nM) or VIP (0.1-5 nM) repeatedly for 12 min or continuously for 96 min.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.